Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                In Vitro Diagnostics

In Vitro Diagnostics

                        Companion Diagnostics
          Biotin Interference with Troponin Lab Tests - Assays Subject to Biotin Interference
          Direct-to-Consumer Tests
          Nucleic Acid Based Tests


                        Blood Glucose Monitoring Devices
          Drugs of Abuse Tests
          Home Use Tests
          Laboratory Developed Tests
          Precision Medicine
          Tests Used In Clinical Care
          Warfarin INR Test Meters Home
          Medical Devices
          Products and Medical Procedures
          In Vitro Diagnostics
          Companion DiagnosticsIn Vitro Diagnostics Companion Diagnostics
  
  	
    Share
    Post
    Linkedin

    Email
    PrintA companion diagnostic is a medical device, often an in vitro diagnostic (IVD), which provides information that is essential for the safe and effective use of a corresponding drug or biological product.

Companion diagnostics can:

identify patients who are most likely to benefit from a particular therapeutic product,
	identify patients likely to be at increased risk for serious side effects as a result of treatment with a particular therapeutic product; or
	monitor response to treatment with a particular therapeutic product for the purpose of adjusting treatment to achieve improved safety or effectiveness.If the diagnostic test is inaccurate, then the treatment decision based on that test may not be optimal.

Related FDA Guidance Documents

On August 6, 2014, the FDA issued the final guidance, In Vitro Companion Diagnostic Devices, to help companies identify the need for companion diagnostics at an earlier stage in the drug development process and to plan for co-development of the drug and companion diagnostic test. The ultimate goal of the guidance is to stimulate early collaborations that will result in faster access to promising new treatments for patients living with serious and life-threatening diseases.

On July 15, 2016, the FDA released the draft guidance, Principles for Codevelopment of an In Vitro Companion Diagnostic Device with a Therapeutic Product. This guidance document, when finalized, is intended to be a practical guide to assist therapeutic product sponsors and IVD sponsors in developing a therapeutic product and an accompanying IVD companion diagnostic.

On April 13, 2020, the FDA published the final guidance, “Developing and Labeling In Vitro Companion Diagnostic Devices for a Specific Group or Class of Oncology Therapeutic Products," which is intended to facilitate class labeling on diagnostic tests for oncology therapeutic products, where scientifically appropriate. This final guidance discusses considerations for the development and labeling of companion diagnostics to support a broader labeling claim such as use with a specific group of oncology therapeutic products, rather than listing an individual therapeutic product(s).

In a related action, on June 21, 2023, the FDA issued a final guidance, “Oncology Drug Products Used with Certain In Vitro Diagnostic Tests: Pilot Program,” to announce and describe the FDA’s voluntary pilot program for certain CDER-regulated oncology drug products1 used with certain in vitro diagnostic tests. FDA intends to pilot a new approach to provide greater transparency regarding performance characteristics that certain tests for oncology biomarkers used to select certain oncology drug treatments should meet. For additional information on this pilot program, visit Oncology Drug Products Used with Certain In Vitro Diagnostics Pilot Program.

Additional Information

Webinar Presentation - Draft Guidance on “Principles for Codevelopment of an In Vitro Companion Diagnostic Device with a Therapeutic Product"

	Webinar Slides - Draft Guidance on “Principles for Codevelopment of an In Vitro Companion Diagnostic Device with a Therapeutic Product" (PDF - 252KB)
		Webinar Transcript - Draft Guidance on “Principles for Codevelopment of an In Vitro Companion Diagnostic Device with a Therapeutic Product" (PDF - 269KB)
	List of Cleared or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools)
	FDA - Personalized Medicine1For the purposes of this guidance, references to oncology drug products include both human drug products and biological drugs products regulated by CDER, unless otherwise specified. This pilot is currently only available for certain oncology drug products within CDER.

                                                                                  Content current as of:
      06/20/2023
              
              
Regulated Product(s)
		 Medical DevicesIn Vitro Diagnostics

          
                        Companion Diagnostics
          Biotin Interference with Troponin Lab Tests - Assays Subject to Biotin Interference
          Direct-to-Consumer Tests
          Nucleic Acid Based Tests


                        Blood Glucose Monitoring Devices
          Drugs of Abuse Tests
          Home Use Tests
          Laboratory Developed Tests
          Precision Medicine
          Tests Used In Clinical Care
          Warfarin INR Test Meters
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop